|
|
|
PEER-TO-PEER CLINICAL CONVERSATIONS |
|
|
|
|
|
Advantages of Using Novel Imaging in nmCRPC APCCC 2022 - Presentation
|
Michael Morris, MD
|
At the 2022 Advanced Prostate Cancer Consensus Conference (APCCC) Hybrid Meeting, Michael Morris presents on advantages of using novel imaging in nmCRPC.
|
|
|
|
|
|
|
|
|
|
Disadvantages of Using Novel Imaging in nmCRPC APCCC 2022 - Presentation
|
Alberto Briganti, MD, PhD
|
In this presentation, Alberto Briganti presents the disadvantages of using novel imaging in the management of non-metastatic castrate-resistant prostate cancer (nmCRPC) patients.
|
|
|
|
|
|
|
|
|
|
Are We Ready to Change Management, Based on Next-Generation Imaging? NO: APCCC 2022 Presentation
|
Nicolas Mottet, MD, Ph.D.
|
At the 2022 Advanced Prostate Cancer Consensus Conference, Nicolas Mottet presents why we are not ready to change management, based on next-generation imaging.
|
|
|
|
|
|
|
|
|
|
Are We Ready to Change Management, Based on Next-Generation Imaging? YES: APCCC 2022 Presentation
|
Jason Efstathiou, MD
|
At the 2022 Advanced Prostate Cancer Consensus Conference, Jason Efstathiou presents why we are ready to change management, based on next-generation imaging.
|
|
|
|
|
|
|
|
|
Advantages of Using Novel Imaging in nmCRPC
|
Michael Morris, MD
|
The 2022 Advanced Prostate Cancer Consensus Conference (APCCC) Hybrid Meeting included a session on the management of non-metastatic castrate-resistant prostate cancer (nmCRPC), and a presentation by Dr. Michael Morris discussing the advantages of using novel imaging in this disease space.
|
|
|
|
|
|
|
|
|
Disadvantages of Using Novel Imaging in nmCRPC |
Alberto Briganti, MD, Ph.D. |
In this presentation, Alberto Briganti discusses the disadvantages of using novel imaging in this disease space. Novel imaging approaches represent sensitive options to detect metastatic sites in men with CRPC. The proven benefit of using novel imaging approaches is unclear given the lack of evidence based on all mentioned limitations regarding patient selection, imaging interpretation and standardization, prospective data of metastasis directed therapy and follow-up assessment. |
|
|
|
|
Are We Ready to Change Management, Based on Next-Generation Imaging? YES
|
Jason Efstathiou, MD
|
In this discussion, Jason Efstathiou argues for changes in management based on next-generation imaging. There is a clinically unmet need for more sensitive and specific imaging with improved characterization/localization of clinically relevant tumor burden. The stage is set for widespread use of PSMA PET/CT and it is becoming the new standard of care for imaging prostate cancer.
|
|
|
|
|
Are We Ready to Change Management, Based on Next-Generation Imaging? NO
|
Nicolas Mottet, MD, Ph.D.
|
Nicolas Mottet argues that we are not ready for changes in management based on next-generation imaging. Dr. Mottet emphasizes that what we are discussing is the everyday use of upfront PSMA PET/CT for staging, outside of a clinical trial, leading to guideline recommendations.
|
|
|
|
|
Prevalence and Natural History of Non-Metastatic Castrate Resistant Prostate Cancer: A Population-Based Analysis |
Amanda E. Hird, MD |
Amanda Hird presents the results of a population-based analysis assessing the prevalence and natural history of non-metastatic castrate resistant prostate cancer (nmCRPC). The natural history of nmCRPC prior to the introduction of novel anti-androgen agents in a real-world setting is largely unknown. Thus, the objective of this study was to determine the prevalence and natural history of nmCRPC in a large historical population-based cohort prior to the adoption of androgen receptor axis-targeting therapies (ARAT). |
|
|
|
|
|